Research Advances in the Treatment of B-Cell Acute Lymphoblastic Leukemia Based on Surface Antigen Expression --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 648-652, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-880128
ABSTRACT
B-cell acute lymphoblastic leukemia (B-ALL) is a common malignant tumor in hematopoietic system. Although the remission rate of the patients with adult B-ALL is similar to those with childhood B-ALL, the rate of long-term disease-free survival (DFS) rate is significantly lower, once recurrence, the remission rate of routine chemotherapy is low and the prognosis is so poor. Based on the expression of tumor cell surface antigens(such as CD19, CD20 and CD22), the specific monoclonal antibodies, bispecific antibodies and chimeric antigen receptor T cells (CAR-T), and other targeted immunotherapy can greatly improve the efficacy of B-ALL patients, especially for patients with relapse and refractory. In this review, the progress of immunotherapy against B-ALL cell surface antigen is summarized briefly.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Linfócitos B
/
Receptores de Antígenos de Linfócitos T
/
Imunoterapia Adotiva
/
Linfoma de Burkitt
/
Antígenos CD19
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Antígenos de Superfície
Limite:
Adulto
/
Criança
/
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS